Discovery

We put creative minds to work.
Neurim Pharmaceuticals Ltd. is a drug discovery and development company, focused on the central nervous system (CNS), primarily in age-related disorders.

Research

Inspiring innovative research.
Through academic research on neurobiology, we hypothesized that age-related sleep complaints are linked to the decay in production of melatonin.

Pipeline

Drugs for better quality of life.

The development of Circadin®, the first and only IP-protected prolonged-release melatonin containing ethical drug, mimics the physiological secretion profile of melatonin.

Neurim Pharmaceuticals

Neurim Pharmaceuticals is a neuroscience drug discovery and development company creating drugs for brain restoration & reinforcement, focusing on the central nervous system.

Its first approved drug, Circadin® – prolonged release melatonin for insomnia is commercially available in Europe, Asia-Pacific, Latin America, Africa and the Middle East.

Neurim Pharmaceuticals has a promising pipeline of New Chemical Entities effective in Central Nervous System disorders.
The company focuses on the diseases of aging, such as insomnia and neuro-degenerative diseases, with the goal of improving quality of life.

  • Text size: A A A
  • Circadin
  • Recent news

    • Slenyto® (PedPRM) was approved by EMA for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient
    • NEURIM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION FOR SLENYTO® (PEDIATRIC PROLONGED-RELEASE MELATONIN) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH AUTISM SPECTRUM DISORDER (ASD)
    • Neurim Pharmaceuticals attends the INSAR Congress in Rotterdam, The Netherlands, May 9-11, 2018
  • Partners

    Partners